+

WO2006102979A3 - Marqueurs d'inflammation et combinaisons de ces marqueurs en tant que marqueurs biochimiques pour des maladies cardio-vasculaires - Google Patents

Marqueurs d'inflammation et combinaisons de ces marqueurs en tant que marqueurs biochimiques pour des maladies cardio-vasculaires Download PDF

Info

Publication number
WO2006102979A3
WO2006102979A3 PCT/EP2006/002230 EP2006002230W WO2006102979A3 WO 2006102979 A3 WO2006102979 A3 WO 2006102979A3 EP 2006002230 W EP2006002230 W EP 2006002230W WO 2006102979 A3 WO2006102979 A3 WO 2006102979A3
Authority
WO
WIPO (PCT)
Prior art keywords
markers
cardiovascular diseases
combinations
inflammation
biochemical
Prior art date
Application number
PCT/EP2006/002230
Other languages
German (de)
English (en)
Other versions
WO2006102979A2 (fr
Inventor
Stefan Blankenberg
Hans J Rupprecht
Christoph Bickel
Original Assignee
Univ Mainz Johannes Gutenberg
Stefan Blankenberg
Hans J Rupprecht
Christoph Bickel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE200510014752 external-priority patent/DE102005014752A1/de
Application filed by Univ Mainz Johannes Gutenberg, Stefan Blankenberg, Hans J Rupprecht, Christoph Bickel filed Critical Univ Mainz Johannes Gutenberg
Publication of WO2006102979A2 publication Critical patent/WO2006102979A2/fr
Publication of WO2006102979A3 publication Critical patent/WO2006102979A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne de nouveaux marqueurs de l'inflammation vasculaire et des combinaisons de ces marqueurs en tant qu'outils pour le diagnostic et le pronostic chez des patients souffrant de maladies cardio-vasculaires. Ces marqueurs servent en outre comme outils facilitant la sélection de principes actifs pour le traitement de telles maladies, ainsi que comme point de départ pour le traitement de maladies cardio-vasculaires. L'invention concerne en outre la création d'un profil de risque individuel d'événements négatifs qui sont liés au développement de l'artériosclérose.
PCT/EP2006/002230 2005-03-31 2006-03-10 Marqueurs d'inflammation et combinaisons de ces marqueurs en tant que marqueurs biochimiques pour des maladies cardio-vasculaires WO2006102979A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66694805P 2005-03-31 2005-03-31
US60/666,948 2005-03-31
DE102005014752.6 2005-03-31
DE200510014752 DE102005014752A1 (de) 2005-03-31 2005-03-31 Entzündungsmarker und Kombinationen davon als biochemische Marker bei kardiovaskulären Erkrankungen

Publications (2)

Publication Number Publication Date
WO2006102979A2 WO2006102979A2 (fr) 2006-10-05
WO2006102979A3 true WO2006102979A3 (fr) 2007-04-26

Family

ID=36579585

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/002230 WO2006102979A2 (fr) 2005-03-31 2006-03-10 Marqueurs d'inflammation et combinaisons de ces marqueurs en tant que marqueurs biochimiques pour des maladies cardio-vasculaires

Country Status (1)

Country Link
WO (1) WO2006102979A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2147115A4 (fr) * 2007-04-16 2010-05-05 Cardibioindice/cardibioscore et utilité d'un protéome salivaire dans des diagnostics cardiovasculaires
EP2319924B1 (fr) * 2008-08-15 2016-03-09 Fujikura Kasei Co., Ltd. Marqueur polypeptidique pour le diagnostic de l'artériosclérose, procédé de détection de l'artériosclérose à l'aide du marqueur ou similaire, et trousse de diagnostic de l'artériosclérose
EP2894473B1 (fr) * 2009-08-28 2016-09-21 Astute Medical, Inc. Procédés et compositions pour le diagnostic et le pronostic de lésion rénale et d'insuffisance rénale
CN102175873A (zh) * 2011-01-11 2011-09-07 江苏迈迪基因生物科技有限公司 心脑血管疾病蛋白标志物的联合并行检测方法及其诊断试剂盒
CN102680697B (zh) * 2011-03-10 2015-11-25 王迎峰 检测肌钙蛋白i的试剂盒及其制备和使用方法
CN110763839A (zh) * 2019-10-31 2020-02-07 安徽大千生物工程有限公司 一种timp-i胶乳增强比浊法检测试剂盒及其制备使用方法
WO2024037387A1 (fr) * 2022-08-19 2024-02-22 Tianjin Yunjian Medical Technology Co., Ltd. Biomarqueurs sanguins et procédés de diagnostic de la maladie de kawasaki aiguë

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ANKERSMIT, H.J., ET AL: "Increased serum concentrations of soluble CD95/Fas and caspase 1/ICE in patients with acute angina", HEART, vol. 90, 2004, pages 151 - 154, XP002416906 *
BENJAFIELD, A.V., ET AL: "Tumor necrosis factor receptor 2 gene (TNFRSF1B) in genetic basis of coronary artery disease", JOURNAL OF MOLECULAR MEDICINE, vol. 79, 2001, pages 109 - 115, XP002416905 *
BICKEL, C., ET AL: "Relation of Markers of Inflammation (C-Reactive Protein, Fibrinogen, von Willebrand Factor, and Leukocyte Count) and Statin Therapy to Long-Term Mortality in Patients With Angiographically Proven Coronary Artery Disease", THE AMERICAN JOURNAL OF CARDIOLOGY, vol. 89, 15 April 2002 (2002-04-15), pages 901 - 908, XP002316705 *
BLANKENBERG, S., ET AL: "Haplotypes of the Caspase-1 Gene, Plasma Caspase-1 Levels and Cardiovascular Risk", CIRCULATION RESEARCH, vol. 99, no. 1, 2006, XP002416907 *
ECONOMOU, E., ET AL: "Serum levels of interleukin-1beta converting enzyme/caspase-1 can be used to detect and quantify apoptotic process in patients with coronary artery disease undergoing percutaneous transluminal coronary angioplasty", EUROPEAN HEART JOURNAL, ABSTRACT SUPPLEMENT, vol. 21, 2000, pages 158, XP009077827 *
LYUTOVA L V ET AL: "53. High fibrinogen level as an early criterion of the cardio-vascular disease (CVD)", FIBRINOLYSIS, CHURCHILL LIVINGSTONE, LONDON, GB, vol. 10, May 1996 (1996-05-01), pages 16 - 17, XP004920960, ISSN: 0268-9499 *
MA, J., ET AL: "A Prospective Study of Fibrinogen and Risk of Myocardial Infarction in the Physicians' Health Study", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 33, no. 5, 1999, pages 1347 - 1352, XP002386351 *
PANAGIOTAKOS D B ET AL: "The associations between leisure-time physical activity and inflammatory and coagulation markers related to cardiovascular disease: the ATTICA Study", PREVENTIVE MEDICINE, ACADEMIC PRESS, XX, vol. 40, no. 4, 25 August 2004 (2004-08-25), Online, pages 432 - 437, XP004626943, ISSN: 0091-7435 *
PORSCH-OEZCUERUEMEZ, M., ET AL: "Evaluation of Serum Levels of Solubilized Adhesion Molecules and Cytokine Receptors in Coronary Heart Disease", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 34, no. 7, 1999, pages 1995 - 2001, XP002416904 *
ROSSI, M. L., ET AL: "Different Quantitative Apoptotic Traits in Coronary Atherosclerotic Plaques From Patients With Stable Angina Pectoris and Acute Coronary Syndromes", CIRCULATION, vol. 110, 2004, pages 1767 - 1773, XP002416903 *
SARASTE, A., ET AL: "Soluble tumor necrosis factor receptor levels identify a subgroup of heart failure patients with increased cardiomyocyte apoptosis", CLINICA CHIMICA ACTA, vol. 320, 2002, pages 65 - 67, XP002416902 *
TZIAKAS, D., ET AL: "Prolonged activation of Tumor necrosis factor (TNF)-a and its soluble receptors in chronic heart failure patients both in the compensated and decompensated state. Interplay between their levels and metalloproteinase-3", EUROPEAN CYTOKINE NETWORK, vol. 15, no. 3, September 2004 (2004-09-01), pages 231 - 239, XP002416901 *

Also Published As

Publication number Publication date
WO2006102979A2 (fr) 2006-10-05

Similar Documents

Publication Publication Date Title
WO2004046722A3 (fr) Scd40l et facteur de croissance placentaire (pigf) servant de combinaisons de marqueurs biochimiques pour des maladies cardiovasculaires
WO2006003388A3 (fr) Compositions et procedes pour le traitement de troubles inflammatoires
WO2007109236A8 (fr) Empreintes digitales micro-arn pendant une mégacaryocytopoïese
WO2006091459A3 (fr) Compositions et methodes permettant de traiter la permeabilite vasculaire
WO2006093348A3 (fr) Procede et composition destines au traitement des maladies vasculaires peripheriques
WO2005077093A3 (fr) Fabrication d'enzymes lysosomales hautement phosphorylees et utilisations associees
TW200709817A (en) Platform antibody compositions
WO2006102979A3 (fr) Marqueurs d'inflammation et combinaisons de ces marqueurs en tant que marqueurs biochimiques pour des maladies cardio-vasculaires
WO2006124748A3 (fr) Composes polycycliques et procedes pour les utiliser
WO2007061939A3 (fr) Dérivés de métabolites de l'inhibiteur de hdac fk228
EP1904111A4 (fr) Compositions et procédés pour diminuer l'expression de microarn pour le traitement de la néoplasie
WO2008153705A3 (fr) Procédés de traitement, de diagnostic et de détection de troubles liés à fgf21
WO2006044825A3 (fr) Inhibiteurs de la kinesine mitotique et methodes d'utilisation desdits inhibiteurs
WO2006058868A8 (fr) Pteridines substituees destinees au traitement de maladies inflammatoires
WO2006102061A3 (fr) Methode de reduction de la calcification
WO2007012057A3 (fr) Composition a base d'eau de vegetation destinee au traitement d'affections cutanees inflammatoires
WO2005075665A3 (fr) Agents diagnostiques et therapeutiques pour des maladies associees a la kallikreine plasmatique (klkb1)
WO2005116088A3 (fr) Methodes et compositions pour traiter des maladies et des troubles associes a des cellules exprimant siglec-8
WO2006128041A3 (fr) Compositions et procedes destines a traiter ou a prevenir un neoplasme chimiomoresistant
WO2005074375A3 (fr) Inhibiteurs de l'heparanase et utilisations
WO2006079068A3 (fr) Compositions et methodes permettant d'etudier et de traiter des maladies et des troubles inflammatoires
WO2006003492A3 (fr) Compositions et methodes de traitement d'infections pathologiques
WO2006034512A3 (fr) Composes a base de quinoleine et de quinazoline a substitution de phenylique pour le traitement du diabete
TW200716561A (en) P38 inhibitors and methods of use thereof
WO2004110365A3 (fr) Compositions et methodes destinees au traitement de maladies hepatiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06723344

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6723344

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载